QBIO: AI 评分 57/100 — AI 分析 (4月 2026)

Q BioMed Inc. is a biomedical acceleration and development company focused on licensing and acquiring life sciences and healthcare assets. They offer a radiopharmaceutical therapeutic for metastatic bone cancer pain and are developing treatments for glaucoma, autism spectrum disorder, and liver cancer.

Key Facts: AI Score: 57/100 Sector: Healthcare

公司概况

概要：

Q BioMed Inc. operates as a biomedical accelerator, acquiring and developing life science assets, including a marketed radiopharmaceutical for bone cancer pain and preclinical candidates targeting glaucoma, autism spectrum disorder, and liver cancer. The company focuses on unmet medical needs within the biotechnology sector.

QBIO是做什么的？

Q BioMed Inc., established in 2013 and based in New York City, is a biomedical acceleration and development company. Originally named ISMO Tech Solutions, Inc., the company rebranded in July 2015 to reflect its focus on acquiring and developing promising life science assets. Q BioMed's core strategy involves licensing and acquiring undervalued or under-resourced life sciences and healthcare companies, providing them with the necessary resources to advance their development programs. The company's portfolio includes Strontium Chloride SR89 and Metastron, radiopharmaceutical therapeutics used for the treatment of metastatic bone cancer pain. Additionally, Q BioMed is actively developing a pipeline of preclinical candidates, including Man-01 for primary open angle glaucoma, QBM-001 for rare pediatric non-verbal autism spectrum disorder, and Uttroside-B for liver cancer. The company also has a partnership with Mannin Research Inc. to develop therapeutics for conditions such as acute respiratory distress syndrome, glaucoma, and kidney diseases. With a small team of 3 employees, Q BioMed operates with a lean structure, focusing on strategic partnerships and efficient resource allocation to advance its development programs.

QBIO的投资论点是什么？

Q BioMed Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's current marketed product, Strontium Chloride SR89, generates revenue, but the company's future growth depends heavily on the successful development and commercialization of its pipeline assets. Key value drivers include the advancement of Man-01 into clinical trials for glaucoma and positive clinical data for QBM-001 in autism spectrum disorder. The company's small size and limited resources pose significant risks, requiring careful monitoring of cash burn and potential dilution. The negative profit margin of -721.7% and gross margin of -3.2% highlight the company's current financial challenges. Investors should closely evaluate the clinical trial timelines and regulatory pathways for Q BioMed's pipeline candidates.

QBIO在哪个行业运营？

Q BioMed Inc. operates within the competitive biotechnology industry, characterized by high research and development costs, lengthy regulatory approval processes, and significant clinical trial risks. The market for cancer therapeutics, particularly radiopharmaceuticals, is growing, driven by an aging population and increasing cancer incidence. The glaucoma and autism spectrum disorder markets also represent significant opportunities, but competition from established pharmaceutical companies and other biotech firms is intense. Q BioMed's success depends on its ability to efficiently develop and commercialize its pipeline assets in a cost-effective manner.

Biotechnology

Healthcare

QBIO有哪些增长机遇？

Advancement of Man-01 for Glaucoma Treatment: The global glaucoma market is projected to reach $5.9 billion by 2027. Q BioMed's Man-01, a pre-clinical lead candidate, represents a significant growth opportunity if it successfully transitions into clinical trials and demonstrates efficacy. The company's partnership with Mannin Research Inc. could accelerate the development process. Timeline: Initiate Phase 1 trials by late 2026.
Development of QBM-001 for Autism Spectrum Disorder: The market for autism spectrum disorder treatments is expanding, with increasing awareness and diagnosis rates. QBM-001 targets a specific subset of patients with rare pediatric non-verbal autism, offering a potentially targeted therapy. Positive pre-clinical data and successful Phase 1 trials could drive significant value. Timeline: Initiate Phase 1 trials by early 2027.
Commercial Expansion of Strontium Chloride SR89 and Metastron: While already marketed, Strontium Chloride SR89 and Metastron offer opportunities for expanded commercialization through strategic partnerships and geographic expansion. Focusing on underserved markets and optimizing distribution channels could increase revenue. The market for bone cancer pain therapeutics is expected to grow steadily. Timeline: Ongoing efforts to expand market reach.
Licensing and Acquisition of New Assets: Q BioMed's core strategy involves acquiring and licensing promising life science assets. Identifying and securing undervalued or under-resourced assets with strong potential could fuel future growth. A disciplined approach to due diligence and strategic partnerships is crucial. Timeline: Ongoing evaluation of potential acquisition targets.
Development of Uttroside-B for Liver Cancer: The global liver cancer therapeutics market is expected to grow, driven by increasing incidence rates. Uttroside-B represents a potential new treatment option. Successful pre-clinical development and subsequent clinical trials are essential for realizing this growth opportunity. Timeline: Advance to IND-enabling studies by mid-2027.

Q BioMed Inc. operates in the biotechnology sector, focusing on acquiring and developing life science assets.
The company's portfolio includes Strontium Chloride SR89 and Metastron, radiopharmaceutical therapeutics for metastatic bone cancer pain.
Q BioMed is developing Man-01 for primary open angle glaucoma, currently in the pre-clinical stage.
The company is also developing QBM-001 for rare pediatric non-verbal autism spectrum disorder.
Q BioMed has a partnership with Mannin Research Inc. to develop therapeutics for acute respiratory distress syndrome, glaucoma, and kidney diseases.

QBIO提供哪些产品和服务？

Acquires and licenses life science and healthcare assets.
Develops therapeutics for unmet medical needs.
Markets Strontium Chloride SR89 and Metastron for metastatic bone cancer pain.
Advances pre-clinical candidates for glaucoma, autism spectrum disorder, and liver cancer.
Partners with other companies to develop new therapies.
Provides resources to accelerate the development of acquired assets.

QBIO如何赚钱？

Acquire or license promising drug candidates or technologies.
Develop these assets through preclinical and clinical studies.
Seek regulatory approval for new therapies.
Commercialize approved products directly or through partnerships.

Hospitals and oncology clinics using Strontium Chloride SR89 and Metastron.
Patients suffering from metastatic bone cancer pain.
Potential future patients with glaucoma, autism spectrum disorder, and liver cancer.
Pharmaceutical companies interested in licensing or acquiring Q BioMed's assets.

Proprietary drug formulations for Strontium Chloride SR89 and Metastron.
Intellectual property rights for pipeline candidates like Man-01, QBM-001, and Uttroside-B.
Established relationships with researchers and clinicians.
Expertise in acquiring and developing undervalued life science assets.

什么因素可能推动QBIO股价上涨？

Upcoming: Initiation of Phase 1 clinical trials for Man-01 in glaucoma (projected by late 2026).
Upcoming: Initiation of Phase 1 clinical trials for QBM-001 in autism spectrum disorder (projected by early 2027).
Ongoing: Commercial expansion efforts for Strontium Chloride SR89 and Metastron.
Ongoing: Evaluation and potential acquisition of new life science assets.
Upcoming: Advancement of Uttroside-B to IND-enabling studies (projected by mid-2027).

QBIO的主要风险是什么？

Ongoing: Limited financial resources and high cash burn rate.
Potential: Clinical trial failures for pipeline candidates.
Potential: Regulatory setbacks and delays in drug approval.
Ongoing: Competition from established pharmaceutical companies.
Potential: Product liability claims and intellectual property disputes.

QBIO的核心优势是什么？

Marketed products generating revenue (Strontium Chloride SR89 and Metastron).
Diverse pipeline of preclinical candidates targeting multiple therapeutic areas.
Partnership with Mannin Research Inc.
Experienced management team in life sciences.

QBIO的劣势是什么？

Limited financial resources and high cash burn.
Dependence on successful development of pipeline assets.
Small team size and limited infrastructure.
Negative profit and gross margins.

QBIO有哪些机遇？

Advancement of Man-01 into clinical trials for glaucoma.
Positive clinical data for QBM-001 in autism spectrum disorder.
Strategic partnerships for commercialization and development.
Acquisition of new promising life science assets.

QBIO面临哪些威胁？

Clinical trial failures and regulatory setbacks.
Competition from established pharmaceutical companies.
Inability to secure funding for continued development.
Product liability claims and intellectual property disputes.

QBIO的竞争对手是谁？

Nanolix Inc — Focuses on nanotechnology-based drug delivery systems. — (NNLX)
Ozy Media Inc — Operates in the media and entertainment industry, unrelated to Q BioMed's core business. — (OZYMF)
Pardes Biosciences Inc. — Develops antiviral therapies for infectious diseases. — (PARD)
Paxmedica Inc. — Focuses on developing therapies for neurological disorders, including autism spectrum disorder. — (PXMD)
Rcarla Inc — Unknown business focus based on provided data. — (RCAR)

Key Metrics

MoonshotScore: 57/100

Company Profile

CEO: Denis D. Corin
Headquarters: New York City, US
Employees: 3
Founded: 2015

AI Insight

AI analysis pending for QBIO

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Q BioMed Inc. do?

Q BioMed Inc. is a biomedical acceleration and development company that focuses on acquiring, licensing, and developing promising life science assets. The company's current portfolio includes Strontium Chloride SR89 and Metastron, radiopharmaceutical therapeutics for metastatic bone cancer pain. Additionally, Q BioMed is developing a pipeline of preclinical candidates targeting conditions such as glaucoma, autism spectrum disorder, and liver cancer. The company aims to address unmet medical needs by providing resources and expertise to advance the development of innovative therapies.

What do analysts say about QBIO stock?

As of 2026-03-17, formal analyst ratings and price targets for QBIO are Unknown, likely due to its OTC listing and small market capitalization. Investors should conduct their own due diligence and consider the company's financial condition, pipeline progress, and potential risks before making any investment decisions. Key valuation metrics, such as price-to-earnings ratio, are not meaningful due to the company's negative earnings. Growth considerations center on the successful development and commercialization of its pipeline assets.

What are the main risks for QBIO?

Q BioMed Inc. faces several significant risks, including limited financial resources, high cash burn, and dependence on the successful development of its pipeline assets. Clinical trial failures or regulatory setbacks could severely impact the company's prospects. Competition from established pharmaceutical companies with greater resources poses a constant threat. Additionally, the company's small size and OTC listing increase the risk of liquidity issues and price volatility. Investors should carefully consider these risks before investing in QBIO.